Unknown

Dataset Information

0

Development of an Oral Salmonella-Based Vaccine Platform against SARS-CoV-2.


ABSTRACT: Effective vaccine development for global outbreaks, such as the coronavirus disease 2019 (COVID-19), has been successful in the short run. However, the currently available vaccines have been associated with a higher frequency of adverse effects compared with other general vaccines. In this study, the possibility of an oral bacteria-based vaccine that can be safely used as a platform for large-scale, long-term immunization was evaluated. A well-known Salmonella strain that was previously considered as a vaccine delivery candidate was used. Recombinant Salmonella cells expressing engineered viral proteins related with COVID-19 pathogenesis were engineered, and the formulation of the oral vaccine candidate strain was evaluated by in vitro and in vivo experiments. First, engineered S proteins were synthesized and cloned into expression vectors, which were than transformed into Salmonella cells. In addition, when orally administrated to mice, the vaccine promoted antigen-specific antibody production and cellular immunity was induced with no significant toxicity effects. These results suggest that Salmonella strains may represent a valuable platform for the development of an oral vaccine for COVID-19 as an alternative to tackle the outbreak of various mutated coronavirus strains and new infectious diseases in the future.

SUBMITTER: Yoon W 

PROVIDER: S-EPMC8777945 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9350170 | biostudies-literature
| S-EPMC7349996 | biostudies-literature
| S-EPMC10530581 | biostudies-literature
| S-EPMC8624180 | biostudies-literature
| S-EPMC9144758 | biostudies-literature
| S-EPMC9157036 | biostudies-literature
| S-EPMC7484811 | biostudies-literature
| S-EPMC7349596 | biostudies-literature
| S-EPMC7843096 | biostudies-literature
| S-EPMC8224379 | biostudies-literature